Drug Trial Radar · NCT05289323
Effect of Intrathecal Neostigmine on Post-dural Puncture Headache.
Last checked: Nov 20, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
722
Actual
Start
Apr 25, 2022
Primary completion
Jul 25, 2023
Study completion Jul 25, 2023
Sponsor
- Lead sponsor
- Alexandria UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kasr El Aini Hospital; Fayoum University
- First posted
- Mar 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Intravenous neostigmine was recently reported as an effective treatment for PDPH for parturients after intrathecal (IT) block which is postulated to be through its central effects on CSF secretion and cerebral vascular tone modulation. Intrathecal neostigmine has been investigated widely and found to be an effective adjuvant to bupivacaine for postoperative analgesia. The objective of the current study is to investigate the possible prophylactic role of intrathecal neostigmine as an adjuvant to bupivacaine in reducing the incidence and severity of post-dural puncture headache in parturients scheduled for an elective cesarean section.
Conditions
- Post-Dural Puncture Headache
Interventions
Neostigmine MethylsulfateDrug
0.5 mg ampule (1 ml) will be diluted in 4 ml dextrose 5% to make a solution of 100 μg/ml, 0.2 ml of this solution will be added to 2.5 ml of hyperbaric bupivacaine 0.5 % used for intrathecal injection.
Dextrose 5%/Nacl 0.9% InjDrug
one ml of normal saline 0.9 % will be mixed with 4 ml dextrose 5 % in the five-milliliter syringe. 0.2 ml of this mixture will be prepared at a one-milliliter identical syringe.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of post-dural puncture headacheTime frame: Two times daily for five days after intrathecal block.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Alexandria University
Alexandria, Egypt
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.